Security Snapshot

AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (AGIO) Institutional Ownership

CUSIP: 00847X104

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

235

Shares (Excl. Options)

66,004,721

Price

$37.11

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+2,986,123
Value change
+$129,589,074
Number of holders
235
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
59,771,717
SEC-reported price per share
$35.01
Insider filing price
$35.01
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") is tracked under CUSIP 00847X104.
  • 235 institutions reported positions in Q2 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 232 to 235 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $2,120,792,628 to $2,451,886,653.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 235 institutions filings for Q2 2026.

Open SEC evidence

Security key

00847X104

Latest holder period

Q2 2026

13F holders

235

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
AGIO
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FARALLON CAPITAL MANAGEMENT, L.L.C. 9.9% $239,950,570 5,917,400 Farallon Capital Management, L.L.C. 30 Jun 2026
Farallon Capital Partners, L.P. 8.8% -11% $146,117,182 -$14,583,696 5,159,505 -9.1% Dapice Joshua J. 31 Dec 2025
BlackRock, Inc. 7.8% $150,100,362 4,513,170 BlackRock, Inc. 30 Jun 2025
STATE STREET CORP 5.3% $88,022,666 3,108,145 STATE STREET CORPORATION 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5.3% $104,472,757 3,088,169 Vanguard Capital Management 31 Mar 2026
D. E. SHAW & CO, L.P. 5.1% $85,832,737 3,034,031 D. E. Shaw & Co., L.P. 25 Jun 2026
Lynx1 Capital Management LP 5.1% $105,819,749 3,013,949 Lynx1 Capital Management LP 29 Apr 2026
Paradigm Biocapital Advisors LP 4.9% -6% $115,344,498 -$6,198,499 2,873,555 -5.1% Paradigm BioCapital Advisors LP 30 Sep 2025
ARMISTICE CAPITAL, LLC 4.6% -13% $95,358,760 -$11,235,200 2,716,000 -11% Armistice Capital, LLC 31 Mar 2026

As of 30 Jun 2026, 235 institutional investors reported holding 66,004,721 shares of AGIOS PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (the "Shares") (AGIO). This represents 110% of the company’s total 59,771,717 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
84%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 6,455,997 +12% 0% $239,582,050
FARALLON CAPITAL MANAGEMENT, L.L.C. 9.9% 5,917,400 +4.1% 1.3% $219,594,714
STATE STREET CORP 5.9% 3,533,633 +5% 0% $131,144,972
Lynx1 Capital Management LP 5.7% 3,408,937 +31% 15% $126,505,652
D. E. Shaw & Co., Inc. 5.2% 3,107,005 +16% 0.07% $115,300,956
VANGUARD PORTFOLIO MANAGEMENT LLC 4.8% 2,898,197 +11% 0% $107,552,091
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 2,681,845 +1.9% 0% $99,523,268
ARMISTICE CAPITAL, LLC 4% 2,400,000 -12% 2.5% $89,064,000
Erste Asset Management GmbH 3.6% 2,154,900 -20% 0.64% $81,972,396
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 3.5% 2,110,809 +41% 0.12% $78,332,000
GEODE CAPITAL MANAGEMENT, LLC 2.6% 1,574,268 +7.2% 0% $58,433,490
SUSQUEHANNA INTERNATIONAL GROUP, LLP 2.3% 1,375,558 +2.3% 0.05% $51,046,957
ADAR1 Capital Management, LLC 2.2% 1,288,053 +816% 2.3% $47,799,647
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 2.1% 1,280,044 -19% 0.05% $47,502,433
DIMENSIONAL FUND ADVISORS LP 2.1% 1,248,738 +8.4% 0.01% $46,345,467
GW&K Investment Management, LLC 2% 1,206,615 -0.68% 0.35% $44,777,000
GOLDMAN SACHS GROUP INC 1.9% 1,150,932 +43% 0% $42,711,087
UBS Group AG 1.6% 985,831 +644% 0.01% $36,584,189
MORGAN STANLEY 1.6% 963,255 -0.44% 0% $35,746,419
Nuveen, LLC 1.5% 873,560 +21% 0.01% $32,417,811
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.4% 810,530 +224% 0.01% $30,078,768
Foresite Capital Management VI LLC 1.3% 785,000 +50% 4.5% $29,131,350
CITADEL ADVISORS LLC 1.2% 732,687 +18% 0.02% $27,190,015
AQR CAPITAL MANAGEMENT LLC 1.1% 684,340 +1780% 0.01% $25,395,858
Parkman Healthcare Partners LLC 1.1% 669,046 +66% 2.5% $24,828,297

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
50
Latest
Q2 2026
Rows shown
1-25 of 50
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 66,004,721 $2,451,886,653 +$129,589,074 $37.11 235
2026 Q1 63,077,301 $2,120,792,628 +$71,838,431 $33.83 232
2025 Q4 61,265,073 $1,667,804,671 -$303,649,463 $27.22 237
2025 Q3 63,487,439 $2,545,616,686 +$81,769,351 $40.14 216
2025 Q2 61,683,672 $2,051,725,997 +$65,237,829 $33.26 211
2025 Q1 59,963,279 $1,757,322,194 -$10,187,060 $29.30 216
2024 Q4 59,832,436 $1,966,429,716 +$37,958,970 $32.86 221
2024 Q3 58,096,571 $2,582,267,784 -$8,181,474 $44.43 204
2024 Q2 58,132,966 $2,506,935,894 -$125,225,015 $43.12 203
2024 Q1 61,946,791 $1,811,267,450 +$89,235,062 $29.24 183
2023 Q4 59,884,422 $1,333,701,271 +$15,853,345 $22.27 167
2023 Q3 59,110,077 $1,463,036,585 -$8,921,651 $24.75 142
2023 Q2 59,366,269 $1,679,785,246 +$16,420,594 $28.32 150
2023 Q1 58,996,438 $1,355,139,176 -$9,985,145 $22.97 161
2022 Q4 59,442,573 $1,669,125,079 +$45,133,345 $28.08 156
2022 Q3 57,972,960 $1,639,524,356 -$46,396,034 $28.28 155
2022 Q2 59,017,906 $1,308,562,484 -$21,425,021 $22.17 143
2022 Q1 59,895,743 $1,743,443,247 +$19,219,573 $29.11 146
2021 Q4 59,210,281 $1,947,305,194 -$73,787,635 $32.87 148
2021 Q3 60,890,488 $2,810,077,563 -$244,072,957 $46.15 157
2021 Q2 65,926,694 $3,632,531,095 +$51,380,893 $55.11 179
2021 Q1 65,233,267 $3,366,007,585 +$56,136,770 $51.64 168
2020 Q4 64,981,734 $2,817,090,446 -$19,419,372 $43.33 189
2020 Q3 65,869,834 $2,304,359,620 -$101,763,130 $35.00 206
2020 Q2 67,492,943 $3,609,431,770 -$76,258,753 $53.48 205
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .